ATR is a large, 4300 kDa protein containing a carboxy-terminus kinase domain related to PI-3 kinase, and is homologous to the ATM gene product in human cells and the rad3/MEC1 proteins in yeast. These proteins, together with the DNA-PK, are part of a new family of PI-3 kinase related proteins. All members of this family play important roles in checkpoints which operate to permit cell survival following many forms of DNA damage. We have expressed ATR protein in HEK293 cells and puri®ed the protein to near-homogeneity. We show that pure ATR is a protein kinase which is activated by circular single-stranded, doublestranded or linear DNA. Thus ATR is a new member of a sub-family of PIK related kinases, founded by the DNA-PK, which are activated in the presence of DNA. Unlike DNA-PK, ATR does not appear to require Ku proteins for its activation by DNA. We show directly that, like ATM and DNA-PK, ATR phosphorylates the genome surveillance protein p53 on serine 15, a site which is up-regulated in response to DNA damage. In addition, we ®nd that ATR has a substrate speci®city similar to, but unique from, the DNA-PK in vitro, suggesting that these proteins have overlapping but distinct functions in vivo. Finally, we ®nd that the kinase activity of ATR in the presence and absence of DNA is suppressed by caeine, a compound which is known to induce loss of checkpoint control. Our results are consistent with the notion that ATR plays a role in monitoring DNA structure and phosphorylation of proteins involved in the DNA damage response pathways.
Introduction
Carcinogenesis appears to be a multistage process, where normal cells progress to benign and ®nally fully malignant forms of cancer through the gradual accumulation of genetic errors (Hartwell and Kastan, 1994; Kinzler and Vogelstein, 1996) . S phase and mitosis, events which are central to cell cycle progression, unavoidably increase the risk to the integrity of the genome of a cell or its progeny. DNA damage, if unrepaired, may result in error propagation during S phase. Similarly, incomplete DNA replication or DNA damage incurred after S phase may be propagated, if not recti®ed prior to mitosis. There is considerable evidence that cells have evolved mechanisms, termed checkpoints, which act to maintain genomic integrity by ensuring that later events in the cell cycle are not initiated if earlier events are incomplete. Defects in cell cycle checkpoints have been proposed to be responsible for the genomic instability of cancer cells (Hartwell and Kastan, 1994) . In addition, it is clear that some tumour cells retain certain checkpoints and are often resistant to treatments designed to damage DNA. It follows that drugs which induce by-pass of checkpoints could be important therapeutically, to augment tumour cell death.
Checkpoints operate at distinct points in the cell cycle, acting to delay transitions from both G1 to S phase and G2 to M phase. In addition, checkpoints monitor M phase exit (Cross and Smythe, 1998) and inhibit DNA replication during S phase if damage to DNA is incurred. The targets of checkpoint signalling pathways are beginning to be elucidated. In the case of G1/S, there is considerable evidence that an end point of this pathway is the stabilization and activation of p53 (Banin et al., 1998; Canman et al., 1998) . In the case of DNA damage-induced S phase arrest, it has been proposed that the DNA replication protein RPA, which binds and stabilizes single-stranded DNA, may be a target (Gately et al., 1998) . Entry into mitosis is dependent both on the repair of DNA damage incurred in the G2 phase of the cell cycle, as well as on the completion of S phase. A large number of observations indicate that this dependence is also the consequence of a DNA structure checkpoint control signalling pathway. Temperature-sensitive mutants have been described in BHK (Nishimoto et al., 1978) , fungal (Osmani et al., 1988) and yeast (al-Khodairy et al., 1994; Weinert and Hartwell, 1988) model cell systems, which allow cells arrested in S phase or G2 to enter mitosis at the restrictive temperature. In S. pombe, these include the genes rad1, rad3, rad9, rad17, rad26, hus1, cds1 and chk1 (Martinho et al., 1998) . Defects in these genes result in loss of checkpoint function with normal cell cycle progression in the presence of either damaged or unreplicated DNA. Recent work has identi®ed the mitotic inducer cdc25 as the target for this checkpoint pathway. Chk1 and cds1 are protein kinases which, when active, phosphorylate cdc25 (Zeng et al., 1998) . This, in turn, promotes the binding of a 14-3-3 protein (Furnari et al., 1997; Peng et al., 1997; Sanchez et al., 1997) , which escorts cdc25 out of the nucleus and thus prevents activation of the mitotic cyclin B/cdc2 kinase (Lopez-Girona et al., 1999).
rad3 is a member of a newly emerging family of proteins termed the PIK-related kinase family whose kinase domain resembles that of the lipid kinase phosphatidylinositol 3-kinase (PI-3 kinase (Hunter, 1995) ). This family includes the DNA-activated protein kinase DNA-PK, which is involved in controlling double-strand break repair and V(D)J joining. This protein consists of a 460 kDa catalytic subunit whose kinase activity is enhanced by ends of DNA molecules in the presence of the co-factors Ku70 and 86 (Jackson and Jeggo, 1995) . In addition, the PIK family includes the TOR proteins, which are targets of the FKBP-rapamycin complex (Brown and Schreiber, 1996; Hall, 1996) , and the ataxia telangiectasia gene product, ATM (Savitsky et al., 1995) . A subset of the PIK family contains an additional region of homology termed the rad3 homologous region, and this subfamily includes the S. cerevisiae MEC1 and TEL1 (Greenwell et al., 1995; Morrow et al., 1995) and the Drosophila mei-41 gene product (Hari et al., 1995) . Mutants in mec1, mei-41 and rad3 all display increased radiation sensitivity and are de®cient in cell cycle checkpoints which prevent mitosis in the presence of unreplicated or damaged DNA. In the case of rad3, site-directed mutations in conserved regions of the kinase domain also abrogate function . More recently, a human homologue of rad3 has been described Cimprich et al., 1996) . This protein, termed ATR (for ATM and rad3 related) can complement the UV sensitivity of mec1 mutants when expressed in S. cerevisiae, and expression of kinase-dead ATR protein in human cells causes sensitivity to DNA damaging agents and defects in cell cycle checkpoints (Cliby et al., 1998; Wright et al., 1998) . Immunoprecipitates of ATR have associated protein kinase activity which is reduced in immunoprecipitates of putative kinase-dead protein (Canman et al., 1998; Keegan et al., 1996; Sarkaria et al., 1998; Tishko et al., 1997) .
In an eort to examine and understand the molecular mechanism by which ATR might exert its cellular eects, we have expressed and puri®ed the full length wild-type and kinase-dead ATR in HEK 293 cells in order to characterize the catalytic activity of this protein. Here we show that this protein is a protein kinase with a substrate speci®city similar to, but unique from, the DNA-PK. Importantly, we have found that ATR-mediated phosphorylation of substrates is activated in the presence of naked DNA molecules, and we show that both basal and DNA activated kinase activity is sensitive to inhibition by caeine and the PI-3 kinase inhibitor, LY294002. The DNA-dependent activation of this kinase suggests a mechanism whereby ATR can detect damaged DNA and activate downstream elements of the pathway to block cell cycle progression.
Results

Expression of ATR in HEK293 cells and isolation by glutathione-agarose chromatography
In order to characterize the biochemical properties of the ATR protein, we set out to express the gene product in HEK293 cells. Full length ATR, together with a mutant sequence which results in the introduction of the alteration D2494E in the kinase domain (Schu et al., 1993) , were cloned into the mammalian expression vector pEBG-2T, which contains a GST tag (Sanchez et al., 1994) . HEK293 cells were transfected by a calcium phosphate-mediated protocol and extracts subjected to glutathione-agarose puri®cation (see Materials and methods). Samples were subjected to SDS ± PAGE and either transferred to nitrocellulose (Figure 1a,b) or subjected to autoradiography (Figure 1c ). Blots were probed for ATR expression using either an anti-GST antibody ( Figure  1a ) or antiserum (4779 ) raised against a fragment of recombinant ATR protein (Figure 1b ). Cells transfected with either wild-type (wt) or a putative kinase-dead (kd) ATR expressed a polypeptide of 4250 kDa, which cross-reacted with both anti-GST and anti-ATR antibodies, and which was absent from cells transfected with a control plasmid (con, Figure 1a ,b). Glutathione agarosepuri®ed protein from cells expressing wt ATR, but not kd ATR, underwent phosphorylation ( Figure 1c , wt and kd). Taken together, these results show that 293 cells express both wt and kd ATR protein. The absence of phosphorylation of the kd protein indicates that the wt ATR undergoes autophosphorylation and is therefore active as a protein kinase. We puri®ed both wt and kd ATR by virtue of the expressed GST tag. Cells expressing both forms of the protein were lysed as described in Materials and methods and subjected to glutathione-agarose chromatography. Material eluted with glutathione was subjected to SDS ± PAGE ( Figure  1d ). Both wt and kd proteins migrated as single silverstained bands of Mr4250 kDa.
ATR is a DNA-activated p53 kinase
ATR is a member of the PIK family which includes DNA-PK. DNA-PK phosphorylates p53 in vitro (Lees- Miller et al., 1992) and has recently been shown to act upstream of p53 in response to DNA damage in vivo (Woo et al., 1998) . We therefore wished to establish whether p53 was also a substrate for puri®ed ATR kinase. Glutathione agarose-puri®ed ATR was incubated with recombinant p53 (Hupp et al., 1992) and [ 32 P]ATP. Samples were analysed by SDS ± PAGE and autoradiography. We found that p53 was phosphorylated weakly by wt ATR but not the kinase-dead protein ( Figure 2a ). Since DNA-PK is activated by DNA in vitro, we wished to establish whether the presence of DNA had any eect on the protein kinase activity of ATR. ATR was incubated with p53 as substrate either in the absence or presence of doublestranded plasmid, single-stranded plasmid, or sheared genomic DNA (Figure 2b) . Surprisingly, we found that the presence of all three forms of DNA increased p53 phosphorylation catalysed by wt ATR by approximately threefold (Figure 2b ,c), with no phosphorylation in samples containing kinase-dead protein. These results indicate that phosphorylation of p53 by ATR is activated by DNA.
In a ®rst step towards establishing the properties of DNA which induce activation of ATR, we used singlestranded, double-stranded and sheared genomic DNA to determine the degree of activation of ATR as a function of DNA concentration. We found that all three forms of DNA-activated ATR to approximately the same extent, with optimal activation observed at about 0.15 ± 1.5 ng/ml of DNA (Figure 3a ± c) .
Inhibition of basal and DNA-activated ATR kinase activity by the PI-3 kinase inhibitor LY294002 and by caeine
We have used the ATR kinase assay to identify inhibitors of the ATR protein in vitro. ATR and its homologue in S. pombe, rad3, have been implicated in both the S/M and G2/M checkpoints. In human (Schlegel and Pardee, 1986) , yeast (Osman and McCready, 1998) and Xenopus cell free systems (Smythe and Newport, 1992) , cell cycle arrest induced by these checkpoints has been shown to be suppressed in the presence of caeine. Given the similarity between ATR and PI-3 kinase, we also wished to establish whether inhibitors of the latter protein blocked ATR function. We therefore determined whether ATR kinase was aected by caeine and LY294002. We found that levels of caeine which overcome checkpoint arrest inhibited both basal and DNA-activated ATR kinase activity (Figure 4a ) but did not have an eect on the mitotic cdc2 kinase (data not shown (Crompton et al., 1993; Smythe and Newport, 1992) . Similarly, LY294002 was found to be an eective inhibitor of both basal and DNA-activated ATR kinase activity (Figure 4b ), although the concentration of LY294002 required for inhibition is substantially higher than that required for PI-3 kinase (Cheatham et al., 1994) .
Substrate speci®city of ATR
All the members of the PIK-related kinase family share a highly similar C-terminal catalytic domain with more variable N-terminal regions. We wished to establish whether a highly conserved catalytic domain would result in a common substrate speci®city among members of this family and ATR in particular. In addition to p53, it has been shown that DNA-PK phosphorylates the transcription factor c-jun, the mdm-2 oncogene and replication factor A (RPA). In a ®rst step towards de®ning the substrate speci®city determi- 32 P]ATP in the presence of (a) single-stranded plasmid, (b) double-stranded plasmid or (c) sheared genomic DNA at the concentrations indicated. Samples were subjected to SDS ± PAGE and autoradiography nants for ATR, we wished to identify additional protein substrates for this kinase. Puri®ed ATR or DNA-PK was incubated with these substrates in the absence or presence of sheared genomic DNA and [ 32 P]ATP. As expected, DNA-PK phosphorylated all of the substrates tested (Figure 5a , right-hand panels) in a DNA-dependent manner. However, in contrast, ATR phosphorylated both p53 and c-jun, but not mdm2 or RPA (Figure 5a , left-hand panels). Importantly, both p53 and c-jun phosphorylation by ATR was increased in the presence of DNA.
We wished to determine directly the site(s) on p53 phosphorylated by ATR. DNA-PK has been reported to phosphorylate both serine 15 and serine 37 on p53 in vitro. We therefore compared ATR-mediated phosphorylation of mutant S15A and wild-type p53 (Figure 5b, top panel) . Little or no phosphate incorporation was observed in S15A compared to the wild-type p53. In contrast, DNA-PK phosphorylated both wild-type and S15A forms of p53 (Figure 5b , bottom panel). These data suggested that the major site of p53 phosphorylation by ATR is serine 15. However, threonine 18 is an additional potential phosphorylation site and it was conceivable that the S15A mutation resulted in a conformational alteration which prevented phosphorylation at this site. In order to exclude this possibility, we identi®ed the site of ATR phosphorylation by direct protein micro-sequencing. This showed that the major release of 32 P-label occurred at a position corresponding to serine 15 (Figure 5c ). These data show that, unlike DNA-PK, ATR phosphorylates p53 on serine 15 only.
Discussion
Using HEK293 cells as an expression system, we have isolated wild-type and a putative kinase-dead mutant of the checkpoint protein ATR and investigated their biochemical properties. ATR is a member of the PIK family of proteins all of which contain a C-terminal domain with substantial homology to the lipid kinase, PI-3 kinase (Hunter, 1995) , together with a large Nterminal region of unknown function. Several lines of evidence have suggested that members of this family are protein rather than lipid kinases. Principally, the large subunit of the DNA-PK lacks a conventional protein kinase catalytic domain, but has a PI-3 kinase domain (Hartley et al., 1995) . DNA-PK is clearly a conventional protein kinase and catalyses the phosphorylation of a number of proteins (Hoekstra, 1997) . In the case of ATR, several workers have reported autophosphorylation of the 4250 kDa polypeptide (Cliby et al., 1998; Keegan et al., 1996) in immunoprecipitates, which was dependent on a functional catalytic domain (Cliby et al., 1998) . However this is not proof that ATR is a conventional protein kinase, as both classical PI-3 kinase (Carpenter et al., 1993; Dhand et al., 1994) and the yeast VPS34 lipid kinase (Stack and Emr, 1994) are capable of carrying out speci®c autophosphorylation, but are clearly lipid kinases in vivo. A number of studies have reported kinase activity associated with ATR in immune complexes, which was reduced but not eliminated in immunoprecipitates of putative kinase-dead protein (Canman et al., 1998 In the absence of analyses of the polypeptide components present in such complexes, this raised the possibility that such complexes contain more than one catalytic activity.
In this work, we have shown that, in addition to autophosphorylation, ATR isolated from HEK293 cells is capable of phosphorylating both p53 and cjun. This activity is intrinsic to the puri®ed ATR protein as the D2494E ATR mutant did not show either auto-phosphorylation or trans-phosphorylation activity. We conclude that ATR is indeed a protein kinase.
We show that, like ATM and DNA-PK, ATR phosphorylates the genome surveillance protein p53 on serine 15 in vitro. This residue is phosphorylated in vivo in response to DNA damage (Banin et al., 1998; Canman et al., 1998) . Phosphorylation at this site is believed to weaken the interaction between p53 and mdm2 (Shieh et al., 1997) , leading to the stabilization of p53 and checkpoint arrest or apoptosis. It has been proposed that both ATM and DNA-PK are directly responsible for the increased phosphorylation of p53 in response to DNA damage as cells lacking either the former or latter protein have reduced levels of p53 phosphorylation (Banin et al., 1998; Canman et al., 1998; Woo et al., 1998) . However, as ATR also phosphorylates p53 at serine 15 in vitro, and as ATR is believed to act downstream of ATM, it is very likely that ATR may also contribute to DNA damageinduced increases in p53 phosphorylation. Consistent with this, while this manuscript was in preparation, Tibbetts et al. reported that expression of kinase-dead ATR in g irradiated cells selectively interfered with late phase serine 15 phosphorylation (Tibbetts et al., 1999) .
Strikingly we have found that phosphorylation of both p53 and c-jun by puri®ed ATR is activated by the presence of DNA. Activation could be achieved using either single-or double-stranded plasmid, or sheared genomic DNA. Taken together these data indicate that ATR is a DNA-activated protein kinase. While this work was in preparation, Gately and colleagues reported that the related protein kinase ATM, could also be activated by DNA (Gately et al., 1998) . Thus DNA-PK is a founding member of a family of kinases which are activated by DNA. Interestingly, DNA-PK interacts with DNA both directly and also by interaction with Ku antigen, a heterodimer of the proteins Ku70/86 (Hammarsten and Chu, 1998). We have blotted our puri®ed ATR preparations and ®nd no evidence for the presence of Ku protein (data not shown). Our results suggest that ATR interacts directly with DNA. However, we cannot exclude the possibility that additional regulation may occur via its association with other polypeptides. The availability of puri®ed ATR and assays for ATR kinase activity will facilitate the identi®cation and characterization of any such polypeptides.
The similarity in the kinase domains of the PIK family members raised the question whether these proteins would have similar substrate speci®cities. Such an outcome would suggest that their distinct in vivo roles are the consequence of speci®c localization and complex formation dependent on the less conserved N-terminal domains. In our experiments, we used DNA-PK as a positive control for the phosphorylation of putative substrates. Like DNA-PK, we found that ATR phosphorylated p53 and cjun. The DNA-PK has been reported to phosphorylate p53 on both Ser-15 and Ser-37 (Lees-Miller et al., 1992) . Consistent with this, we observed ecient and signi®cant phosphorylation of mutant p53 S15A by DNA-PK. In contrast, we observed little or no phosphorylation of p53 S15A by our highly puri®ed ATR preparation. These data contrast with those of Tibbetts et al. (1999) , who reported that immunoprecipitates of ATR protein phosphorylated both serines 15 and 37. There are several potential reasons for this dierence which may be related to dierences in the methods used to obtain ATR. Signi®cant p53 kinase activity was observed with pre-immune sera in that study (Tibbetts et al., 1999) , and it is conceivable that the immunoprecipitates contain, in addition to ATR, other p53 kinases which phosphorylate serine 37. Moreover, the results obtained here utilised wild-type full length p53, while Tibbetts et al. used an Nterminal fragment solely comprising the ®rst 70 amino acids of the protein. In addition we found that RPA and mdm2, both known substrates for DNA-PK, were not substrates for ATR, suggesting that there is likely to be unique range of substrates associated with each member of the PIK family.
RPA has been proposed to be the in vivo target for pathways which induce S phase arrest in response to DNA-damaging agents. Cells derived from patients with ataxia telangiectasia (AT) fail to arrest S phase progression when subjected to ionizing radiation and carry out radioresistant DNA synthesis (RDS). RPA in normal cells but not in AT cells undergoes hyperphos-phorylation in response to ionizing radiation (Liu and Weaver, 1993) . However, a recent report demonstrated that the RDS phenotype in AT cells could be suppressed by the ectopic expression of wild-type ATR (Cliby et al., 1998) . In addition, expression of various fragments of ATM results in the uncoupling of RPA phosphorylation from checkpoint arrest (Morgan and Kastan, 1997) . Coupled with our observation that RPA is not a substrate for ATR, this strongly suggests that some other protein is the target of damage-induced replication arrest.
Expression of kinase-inactive mutants of ATR in human ®broblasts causes loss of G2/M checkpoint control as well as loss of the dependence of mitosis on the completion of S phase (Cliby et al., 1998) . Such data support a role for ATR in these checkpoints. We suggest that insults to the integrity of the genome may be detected by ATR, presumably in association with other checkpoint gene components, resulting in a DNA-mediated activation of the catalytic activity of the ATR protein and the subsequent phosphorylation of down-stream targets resulting in cell cycle arrest. In tissue culture cells and in cell free systems, the dependence of mitosis on the completion of S phase (Schlegel and Pardee, 1986) as well as the G2 DNA damage checkpoint (Downes et al., 1994) can be uncoupled by caeine. We found that levels of caeine which bypass the replication checkpoint inhibited both basal and DNA-stimulated ATR kinase activity, almost to levels achieved with another inhibitor of PIK family kinases, LY294002 (Brunn et al., 1996) . We suggest that ATR may be one target for the caeine-mediated bypass of S phase and G2 checkpoints. It has been suggested that the potency of anti-cancer drugs to kill target cells might be signi®cantly enhanced by the use of adjuvant factors like caeine which inhibit checkpoint pathways. Such adjuvants would be expected to permit cell cycle progression in cells containing substantial DNA damage, giving rise to inviable daughter cells. Irrespective of whether ATR is the sole target of caeine, it remains an excellent candidate for the development of speci®c inhibitors to test the hypothesis.
Materials and methods
Construction of ATR expression vectors
A 542 bp BamHI/MscI DNA fragment consisting of base pairs 1 ± 513 of 5' coding sequence of ATR preceded by the His tag-containing sequence GATCCAGCATGCATCAC-CATCACCATCAC, together with a MscI/SalI fragment comprising base pairs 540 to the end of the ATR coding sequence was assembled into the GST expression vector pEBG-2T (Sanchez et al., 1994) which had been cut with BamHI and SalI, to yield pEBG-wtATR. In order to obtain pEBG-kdATR for expression of D2494E ATR, the MscI/SalI fragment of pEBG-wtATR was excised and replaced with a MscI/NotI fragment containing the appropriate mutation .
Transfections and cell lysis
Human embryonic kidney (HEK) 293 cells were transfected with either the pEBG-wtATR or pEBG-kdATR construct using a calcium phosphate method. Cells were plated at 50% con¯uency in 10 cm dishes and allowed to attach for 2 ± 4 h. Ten mg of DNA was mixed with 61 ml of 2M CaCl 2 and enough H 2 O to bring the total volume to 500 ml. The CaCl 2 / DNA was then added with gentle agitation to 500 ml of 26HBS (0.274 M NaCl, 1.5 mM Na 2 HPO 4 , 54.6 mM HEPES, pH 7.0) and the DNA/CaCl 2 /HBS precipitate added dropwise to the cell medium. Following an 18 h incubation the precipitate was removed and fresh media added to the cells for a further 48 h incubation. Cells were lysed in ice cold lysis buer (20 mM Tris acetate, pH 7.5, 0.27 M sucrose, 1% (by mass) Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM sodium b-glycerophosphate, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 50 mM sodium¯uoride, 0.1% (by vol) 2-mercaptoethanol, complete proteinase inhibitor cocktail (Boehringer Mannheim), the lysates frozen in liquid nitrogen and stored at 7808C until use.
Glutathione-agarose puri®cation of ATR
The cell lysates were spun at 13 000 g for 5 min and the supernatants pooled and incubated at 48C for 1 h with glutathione-agarose beads (Pharmacia Biotech) which had been pre-equilibrated in lysis buer. The beads were then washed four times in lysis buer containing 0.5 M NaCl and then ten times in wash buer (25 mM HEPES, pH 7.6, 20% glycerol, 2 mM MgCl 2 , 0.2 mM EDTA, 250 mM KCL, 0.1% NP-40, 1 mM sodium orthovanadate, 0.1% (by vol) 2-mercaptoethanol). The ATR was either used directly bound to agarose beads or eluted by incubation at 48C for 1 h with kinase buer containing 30 mM glutathione, pH 7.9, (25 mM HEPES, pH 7.9, 50 mM KCl, 10 mM MgCl 2 , 2 mM MnCl 2 , 20% glycerol, 0.1% NP-40, 1 mM DTT, 0.5 mg/ml BSA).
Silver staining of polyacrylamide gels and immunoblotting
Glutathione-puri®ed ATR was subjected to 6% SDS ± PAGE and either silver stained or transferred to nitrocellulose. Immunoblotting was performed using an anti-GST antibody (UBI) and antiserum (4779) raised against a fragment of recombinant ATR protein .
Kinase assays
Kinase assays were performed in 50 ml reactions using 30 ml of puri®ed ATR (approximately 100 ng per 50 ml reaction) or kinase buer, 0.5 ± 1.6 mg substrate (as speci®ed in the text), 1 ng/ml DNA (unless otherwise stated) and 0.1 mM [ 32 P]ATP (1610 6 c.p.m./nmol). Reactions were incubated at 308C for 15 min, stopped by the addition of sample buer and then subjected to SDS ± PAGE and autoradiography. DNA-PK (Promega) was assayed essentially as for ATR except that DNA-PK was diluted in 30 ml kinase buer and used at an activity of 20 U per reaction (®nal protein concentration 150 ng per 50 ml reaction). DNA was either salmon testes DNA (Sigma), redissolved in water, extracted with phenol:chloroform and sheared by passing rapidly through a 21 gauge needle, single stranded M13 plasmid DNA (Pharmacia Biotech), or puri®ed (Qiagen) double-stranded plasmid DNA. c-jun was obtained from Promega. Caeine was obtained from Sigma and LY294002 was from Calbiochem.
Micro-sequencing of p53
A kinase assay was performed in the presence of DNA using puri®ed ATR and p53 as described previously, except that [ 32 P]ATP was used at a speci®c activity of 1610 8 c.p.m./nmol. Reactions were subjected to SDS ± PAGE, transferred to Problot (PE-Biosystems), and proteins visualized using Brilliant Blue R (Sigma). The p53 band was excised and treated with 70% formic acid in water at 458C for 18 h. The membrane was then extracted with 50% acetonitrile/10% TFA and the supernatants combined and dried under vacuum. This procedure resulted in near-quantitative cleavage (470%) of the Asp 7 -Pro 8 bond. Sample was resuspended in 50% acetonitrile /0.1% TFA and coupled to a Sequelon-AA membrane (Millipore) according to the manufacturers instructions. Sample was then subjected to solid phase Edman degradation (Stokoe et al., 1992) and the ATZ-amino acids collected and radioactive content determined by Cerenkov counting.
